Page 1

1 August 2009

CURRICULUM VITAE

Name: Douglas A. Hale, MD, FACS Title: Associate Professor of Surgery Office: Division of Kidney/Pancreas Transplant Vanderbilt University Medical Center 1313 21st Avenue South Oxford House, Suite 912 Nashville, TN 37232-4750 Phone (615) 936-0404 Fax (615) 936-0409 Born: 16 Feb. 1958 Buffalo, New York Education and Honors: Bishop Timon High School Buffalo, New York 1972-1976 New York State Regents Scholarship St. Bonaventure University Olean, New York 1976-1980 B.S. Biology/Chemistry Summa cum Laude American Chemical Society Award Kodak Science Scholarship Association of the Army Medal Georgetown University School of Medicine Washington, D.C. 1980-1984 Doctor of Medicine Alpha Omega Alpha Medical Honor Society Post Graduate Education: PGY-1 Categorical Surgical William Beaumont Army Medical Center El Paso, Texas 1984-1985 General Surgical Residency Walter Reed Army Medical Center Washington, DC 1986-1990

Page 2

Senior Research Fellow 1 July 1995 – 30 June 1998 Division of Organ Transplantation Harvard Medical School New England Deaconess Hospital One Deaconess Road Boston, Massachusetts 02215 Clinical Transplant Surgical Fellow 1 July 1998 – 30 June 2000 Division of Organ Transplantation Harvard Medical School Beth Israel Deaconess Medical Center One Deaconess Road Boston, Massachusetts 02215 Master Medical Educator Course University of Florida, College of Medicine January 2007 – April 2008 Academic Appointments Associate Professor of Surgery University of Florida College of Medicine at Jacksonville 653-1 W. Eighth St. Jacksonville, FL 32209 June 2006 - Present Assistant Professor of Surgery Uniformed Services University of the Health Sciences F. Edward Hebert School of Medicine 4301 Jones Bridge Road Bethesda, Maryland 20814-4799 July 1990 – June 1995 Research Fellow Clinical Fellow in Surgery Harvard Medical School Boston, Massachusetts 1 July 1995 – 30 June 2000 Certification: National Board of Medical Examiners, 1985 Virginia State Medical License Diplomate American Board of Surgery

Page 3

Commonwealth of Massachusetts Medical License (Inactive) State of Rhode Island Medical License (Inactive) State of Florida Medical License Associations: Fellow, American College of Surgeons Member, Association for Academic Surgery 1993-2003 Member, Transplantation Society 1998-Present Education Committee 2004 - Present Member, American Society of Transplant Surgeons 2001 – Present

Informatics and Data Management Committee 2003 – 2006 Winter Meeting Planning Committee 2004 – 2005 Winter Meeting Planning Committee 2005-2006 Fellowship Education Committee 2007 - Present Member, American Society of Transplantation 2003 – Present Member, American Medical Association 2006 – Present Member, Florida Medical Association 2006 – Present Member, Duval County Medical Society 2006 – Present Journal and communications Committee 2006 - Present

Page 4

Study Sections: Ad Hoc Reviewer Department of Veterans Affairs Merit Review Subcommittee for Immunology-B 8-9 June 2004 Ad Hoc Reviewer Department of Veterans Affairs Merit Review Subcommittee for Immunology-B 6-7 December 2004 Ad Hoc Reviewer Department of Veterans Affairs Merit Review Subcommittee for Immunology-B 19-20 May 2005 Post Graduate Internship History: 1984-1985 William Beaumont Army Medical Center Group Surgeon 1985-1986 528th USAAG Çakmakli, Turkey General Surgery Resident 1986-1990 Walter Reed Army Medical Center Staff General Surgeon August 1990 - December 1990 US Army MEDDAC Fort Polk, Louisiana 71459-6000 Staff General Surgeon December 1990 - May 1991 15th Evacuation Hospital 18th Airborne Corps Operation Desert Storm Saudi Arabia Staff General Surgeon May 1991 - June 1992 US Army MEDDAC Fort Polk, Louisiana 71459-6000 Attending General Surgeon Surgical Representative: Institutional Review Board

Page 5

Physician Representative: Laboratory Animal Use Committee July 1992 - June 1995 Walter Reed Army Medical Center Washington, DC 20307-5001 Chief of Surgery September 1994- November 1994 28th Combat Support Hospital 82nd Airborne Division Operation Restore Democracy Port au Prince, Haiti Senior Research Fellow 1 July 1995 – 30 June 1998 Division of Organ Transplantation Harvard Medical School New England Deaconess Hospital One Deaconess Road Boston, Massachusetts 02215 Clinical Transplant Surgical Fellow 1 July 1998 – 30 June 2000 Division of Organ Transplantation Harvard Medical School Beth Israel Deaconess Medical Center One Deaconess Road Boston, Massachusetts 02215 Awaited completion of federal government hiring process July and August 2000 Transplant Surgeon/Investigator 1 September 2000 – 31 May 2006 Transplantation Branch/NIDDK/NIH Organ Transplantation Building 10, Room 11S219 10 Center Drive Bethesda, Maryland 20892 Associate Professor of Surgery Division of Transplantation Associate Program Director General Surgery Residency 1 June 2006 – 30 April 2009 University of Florida, Jacksonville 580 West Eighth Street Tower II, Suite 8000 Jacksonville, Florida 32209

Page 6

Associate Professor of Surgery Division of Kidney/Pancreas Transplantation 5 May 2009 - Present Vanderbilt University Medical Center 1313 21st Avenue South Oxford House, Suite 912 Nashville, TN 37232-4750 Awards: Outstanding Abstract/Presentation 11th Ortho Biotech/ASTP Transplant Fellows’ Workshop New Orleans, La 12-14 Nov 1997 Novartis/ASTS Fellowship American Society of Transplant Surgeons Chicago, Illinois 13-15 May 1998 Best Teaching Faculty University of Florida College of Medicine June 2007 Exemplary Educator Award University of Florida College of Medicine April 2008

Approved/Funded Protocols

Douglas A. Hale PI, Small bowel transplantation in non-human primates. 1987 – 1999. Funded by Department of Defense. Douglas A. Hale PI, Regulation of IGF-1 receptor expression in healing tissue. 1992 – 1994. Funded by Department of Defense. Douglas A. Hale PI, Effects of perioperative administration of motilin on postoperative gastric ileus. 1992 – 1995. Funded by Anaquest Pharmaceuticals Group. Douglas A. Hale PI, Review of appendectomies performed in Department of Defense medical facilities. 1992 – 1995. Funded by Department of Defense. Douglas A. Hale PI, Pre-clinical research on the mechanisms underlying the tolerogenic effects of sirolimus when administered in combination with anti-lymphocyte serum and donor specific bone marrow in a rodent model. 1996 – 1998. Funded by Wyeth Ayerst Pharmaceuticals.

Page 7

Douglas A. Hale PI, Role of donor specific thymic chimerism and subsequent centrally mediated clonal deletion in maintaining the tolerogenic effects of sirolimus when administered in combination with anti-lymphocyte serum and donor specific bone marrow in a rodent model. 1998 – 2000. Funded by Wyeth Ayerst Pharmaceuticals. Douglas A. Hale PI, Refinement of ALS/BM/sirolimus based tolerance protocol in a rodent model. 2000 – 2003. NIH Intramural Funding. Douglas A. Hale PI, Production of polyclonal rabbit anti-mouse (mus musculus) anti-lymphocyte serum (ALS) in rabbits (oryctalagus cuniculus). 2002 – 2006. NIH Intramural Funding. Douglas A. Hale PI, Use of donor bone marrow to induce tolerance to skin and kidney allografts in a nonhuman primate model. 2002 – 2006 NIH Intramural Funding. Douglas A. Hale PI, Induction of donor specific immunologic hyporesponsiveness with thymoglobulin, sirolimus and donor bone marrow infusion. 2003 – 2006. NIH Intramural Funding. INDs: BB-IND 10364 Allogeneic Bone Marrow, Anti-Thymocyte Globulin Assigned 14 August 2002 CRADAs: Sangstat January 2001 – January 2004 Sangstat, Wyeth-Ayerst 3 Way CRADA January 2002 – January 2005

Abstract Presentations: 1. Hale DA, Cohen AJ, Schaefer P, Jordan D, Thompson LD, Bellamy RF, Edwards FH, Barry MJ: The Use of Computed Tomography in the Evaluation of Patients with Myasthenia Gravis. Presented at The Seventh Annual USUHS Cardiothoracic Surgery Symposium, 3 June 1989, Washington, DC. 2. Hale DA, Pearl RH, Kleinschmidt J, Waldorf K, Seyfer A: Small Bowel Transplantation in Nonhuman Primates. Presented at the Gary P. Wratten Surgical Symposium, 4 April 1990, Washington, DC. 3. Hale DA, Pearl RH, Kleinschmidt J, Waldorf K, Seyfer A: Small Intestine Transplantation. Presented at the Tenth Annual Uniformed Services University Surgical Associates Day, 6 April 1990, Bethesda, Maryland. 4. Hale DA, Kleinschmidt J, Waldorf K, Pearl RH, Seyfer A. Small intestinal transplantation in non-human primates. Presented at the 59th Annual Meeting of the American Academy of Pediatrics Surgical Section, 6 October 1990, Boston, Massachusetts.

Page 8

5. Sayles J, Hadro N, Hale DA, Molloy M, Pearl RH, Jaques DP. Significance of post thyroidectomy calcium levels. Presented at the Gary P. Wratten Surgical Symposium, 30 March 1993, Denver, Colorado. 6. Starnes B, d'Addio V, Bruderer B, Hale DA. Expanding general surgical applications of laparoscopy. Presented at the Gary P. Wratten Surgical Symposium, 30 March 1993, Denver, Colorado. 7. Goff JM, Molloy M, Debas MT, Hale DA, Jaques DP. Long term followup of needle localization breast biopsy for benign disease. Presented at the Gary P. Wratten Surgical Symposium, 30 March 1993, Denver, Colorado. 8. Hadro NC, Hale DA, Molloy M, Pearl R, Jaques DP. Selective digital enhancement of conventional film mammography. Presented at the Thirteenth Annual Uniformed Services University Surgical Associates Day, 2 April 1993, Bethesda, Maryland. 9. Pearl RH, Hale DA, Molloy M, Schutt DC, Jaques DP. Pediatric Appendectomy. Presented at American Pediatric Surgical Association, 16 April 1994. 10. Galapon D, Pearl RH, Molloy M, Hale DA, Jaques DP. Respiratory complications following modified nessen fundoplication n neurologically impaired children. Presented at the Gary P. Wratten Surgical Symposium, 21 April 1994, Cloudcroft, New Mexico. 11. Batty DS, Hale DA, Molloy M, Pearl RH, Schutt D, Jaques DP. Appendectomy: A current community standard. Presented at the Gary P. Wratten Surgical Symposium, 21 April 1994, Cloudcroft, New Mexico. 12. Starnes B, Kim B, Williams S, Molloy M, Hale DA. Evaluation of breast lesions using technetium-99-sestamibi scintigraphy. Presented at the Gary P. Wratten Surgical Symposium, 22 April 1994, Cloudcroft, New Mexico. 13. Hadro NC, Hale DA, Molloy M, Pearl R, Jaques DP. Selective digital enhancement of conventional film mammography. Presented at the Gary P. Wratten Surgical Symposium, 22 April 1994, Cloudcroft, New Mexico. 14. Lane B, Hale DA, Molloy M, Batzri S. Increased IGF-1 receptors in skin wounds healing by secondary intention. Presented at the Surgical Forum, American College of Surgeons, 10 October 1994, Chicago, Illinois. 15. Molloy M, Hale DA, Goldberg W, Batzri S, Harmon J. Transient bile salt-induced intracellular hypercalcemia - a recurring challenge for gastric mucosal cells. Presented at the 8th International Conference on Ulcer Research, 20 November 1994, Kyoto, Japan. 16. Maniscalco-Theberge ME, Brengman ML, Fleischer GD, Hale DA, Jaques DP. The utilization of directed clinical evaluation to eliminate routine chest x-rays in intensive care unit patients. Presented at Eastern Association for the Surgery of Trauma, February 1995, Philadelphia, Pennsylvania.

Page 9

17. Garrett M, Hale DA. Incidence of neurogenic shock in penetrating versus blunt spinal cord injuries. Presented at Gary P. Wratten Surgical Symposium, 3 May 1995 Boston, Massachusetts. 18. Lane B, Hale DA. Increased expression of insulin-like growth factor I receptors occurs during wound healing by secondary intention. Presented at Gary P. Wratten Surgical Symposium, 4 May 1995 Boston, Massachusetts. 19. LeVoyer TE, d'Addio V, Shriver CD, Hale DA, Jaques DP. The Utility of Pre-operative Liver Function Tests and CEA in Colon Cancer: Results of 1321 patients in the DOD Database. Presented at Gary P. Wratten Surgical Symposium, 5 May 1995 Boston, Massachusetts. 20. Shriver CD, Hale DA, Schutt DC, Otchy DP, Jaques DP. Abdominal CT scans prior to colon resection are not indicated if serum CEA is normal: data from 1321 patients over 5 months in the 144 DoD hospitals. Presented at The Clinical Congress, American College of Surgeons, 24 October 1995, New Orleans, Louisiana. 21. Monaco AP, Hale DA, The use of CTLA-4 Ig to prolong allograft survival and induce allograft tolerance. Presented at the 7th Walter Brendel Symposium on Applied Immunology and Microcirculation, Axams, Tirol, Austria, 5 February 96. 22. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Prolongation of skin allograft survival in mice treated with rapamycin, antilymphocyte serum and donor specific bone marrow transfusion. Presented at 2nd International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva, Switzerland, 17 February 1996. 23. Hale DA, Gottschalk R, Wood ML, Maki T, Monaco AP. Prolongation of skin allograft survival in mice treated with CTLA-4Ig in combination with rapamycin or cyclosporine. Presented at 2nd International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva, Switzerland, 17 February 1996. 24. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Skin allograft survival in mice treated with rapamycin, antilymphocyte serum and donor specific bone marrow transfusion. American Society of Transplant Surgeons, Dallas, Texas, 30 May 1996. 25. Hale DA, Gottschalk R, Maki T, Monaco AP. Induction of permanent donor specific tolerance and allogeneic chimerism with a single dose of sirolimus in antilymphocyte serum treated, donor specific bone marrow injected mice. Presented at 4th International Conference on Tolerance Induction, Breckenridge, Colorado, 19 January 1997. 26. Hale DA, Gottschalk R, Maki T, Monaco AP. The mutifactorial basis of donor specific tolerance and chimerism induced with a single dose of sirolimus in antilymphocyte serum (ALS) treated, donor specific bone marrow (BM) injected mice. Presented at the Eleventh Ortho Biotech/ASTP Transplant Fellow’s Workshop, New Orleans, Louisianna, 12-14 November 1997. 27. Hale DA, Gottschalk R, Maki T, Monaco AP. The mutifactorial basis of tolerance. Presented at New Dimensions in Transplantation, Florence, Italy, 16-18 February 1998.

Page 10

28. Hale DA, Gottschalk R, Maki T, Monaco AP. The role of clonal deletion in prolonging skin allograft survival in mice treated with antilymphocyte serum, donor specific bone marrow and sirolimus. Presented at American Society of Transplant Surgeons, Chicago, Illinois, 14 May 1998 29. Hale DA, Gottschalk R, Maki T, Monaco AP. Sirolimus facilitates induction of chimerism in antilymphocyte serum treated, donor specific bone marrow injected mice. Presented at the 24th Annual Meeting, American Society of Transplant Surgeons, Chicago, Illinois, 13-15 May 1998. 30. Hale DA, Shaffer D. Vascular access patency in a predominantly diabetic population. Presented at the Joint Plenary Session of New England Surgical Society and the New England Society for Vascular Surgery, Toronto, Ontario, Canada. 20 September 1998. 31. Hale DA, Umemura A, Gottschalk R, Maki T, Monaco AP. Stable donor specific chimerism and tolerance using ALS, sirloimus and donor bone marrow: effects of bone marrow dose on duration of and mechanisms responsible for graft survival. Presented at the 5th International Conference on Tolerance Induction, Breckenridge, Colorado, 26 January 1999. 32. Hale DA, Monaco AP. Tolerance induction: the current state of the art. Presented at the Spring Meeting of the New England Surgical Society, Boston, Massachusetts, 8 May 1999. 33. Hale DA. Tolerance induction with sirolimus, antilymphocyte serum and donor bone marrow. 4th International conference on new trends in clinical and experimental immunosuppression. 18 February 2000, Geneva, Switzerland. 34. Montgomery SP, Mog S, Hale DA, Kirk AD. Toxicity of rapamycin, tacrolimus and daclixumab in the non-human primate. Presented at Transplantation 2001, Chicago, Illinois, 15 May 2000 35. Hale DA, Gottschalk R, Umemura A, Maki T, Monaco AP. Immunologic mechanisms in tolerance induced by non-radiation based immunosuppression and donor bone marrow. Presented at Transplantation 2001, Chicago, Illinois, 15 May 2001 36. Akpinar E, Park J, Chute JP, Harlan DM, Hale DA. Donor bone marrow retains its tolerogenic efficacy following in vitro expansion. Presented at the American Transplant Congress, Washington, D.C., 29 April 2002 37. Xu H, Preston EH, Montgomery SP, Berning JP, Tadaki DK, Hale DA, Harlan DM, Kirk AD. Prolonged non-human primate skin allograft survival with the anti-CD154 antibody IDEC-131 combined with pretransplant donor specific transfusion and rapamycin. Presented at the American Transplant Congress, Washington, D.C., 30 April 2002 38. Hoffmann, SC, Kampen RL, Amur S, Sharaf MA, Kleiner DE, Swanson SJ, Hale DA, Mannon RB, Harlan DM, Blair PJ, Kirk AD. Correlation of intragraft T cell costimulation molecules as surrogate markers of adverse clinical outcomes following renal allotransplantation. Presented at the American Transplant Congress, Washington, D.C., 30 April 2002 39. Kirk AD, Hale DA, Hoffmann SC, Kampen RL, Kleiner DE, Mannon RB, Swanson SJ,

Page 11

Harlan DM. Results from a human tolerance trial using campath-1H with and without infliximab. Presented at the American Transplant Congress, Washington, D.C., 30 April 2002 40. Cendales LC, Hale DA, Mannon RB, Swanson SJ, Harlan DM. Comparison of the magnitude and kinetics of two aggressive depletional strategies, Campath 1H or high dose polyclonal RATG, to conventional RATG with triple immunosuppressive maintenance therapy. Presented at the American Transplant Congress, Washington, D.C., 30 April 2002 41. Hoffmann, SC, Kampen RL, Amur S, Sharaf MA, Kleiner DE, Hunter K, Swanson SJ, Hale DA, Mannon RB, Harlan DM, Blair PJ, Kirk AD. Gene expression and immunohistochemical profile of human renal allograft ischemia-reperfusion injury and resolution. Presented at the American Transplant Congress, Washington, D.C., 1 May 2002 42. Swanson SJ, Hale DA, Mannon RB, Harlan DM, Kleiner DE, Kirk AD. Sirolimus monotherapy in kidney transplantation following high dose thymoglobulin induction. Presented at the American Transplant Congress, Washington, D.C., 1 May 2002 43. Kirk AD, Hale DA, Hoffmann SC, Kampen RL, Kleiner DE, Mannon RB, Swanson SJ, Harlan DM. Results from a human tolerance trial using campath-1H with and without infliximab. Presented at the XIX International Congress of the Transplantation Society, Miami, Florida, 26 August 2002 44. Swanson SJ, Hale DA, Mannon RB, Harlan DM, Kleiner DE, Kirk AD. Sirolimus monotherapy in kidney transplantation following high dose thymoglobulin induction. Presented at the XIX International Congress of the Transplantation Society, Miami, Florida, 26 August 2002 45. Cendales LC, Kleiner D, Burns C, Hale DA, Kirk AK, Granger D, Breidenbach WC. Histopathology of rejection in composite tissue allotransplantation. Presented at the XIX International Congress of the Transplantation Society, Miami, Florida, 26 August 2002 46. Cendales LC, Hale DA, Mannon RB, Swanson SJ, Harlan DM. Comparison of the magnitude and kinetics of two aggressive depletional strategies, Campath 1H or high dose polyclonal RATG, to conventional RATG with triple immunosuppressive maintenance therapy. Presented at the XIX International Congress of the Transplantation Society, Miami, Florida, 29 August 2002 47. Hoffmann S, Kampen R, Amur S, Becker B, Cendales L, Hale DA, Jacobson L, Kleiner D, Mannon R, Muehrer R, Swanson SJ, Kirk AD. Quantitative differences in renal allograft gene expression indicate qualitative changes in the cellular infiltrate differentiating subclinical from clinical acute rejection. Presented at the American Transplant Congress, Washington, D.C., 1 June 2003. 48. Kampen RL, Hoffmann SC, Hale DA, Mannon RB, Cendales LC, Swanson SJ, Kirk AD. Intragraft renal allograft transcriptional analysis during rabbit anti-thymocyte globulin induction and sirolimus monotherapy compared to standard of care triple immunosuppression. Presented at the American Transplant Congress, Washington, D.C., 2 June 2003. 49. Kirk AD, Hale DA, Cendales LC, Hoffmann SC, Kampen RL, Kleiner DE, Mannn RB, Pearl

Page 12

JP, Wakefield T, Swanson SJ. Results from a human tolerance trial using alemtuzumab (campath-1H) with deoxyspergualin (DSG). Presented at the American Transplant Congress, Washington, D.C., 2 June 2003. 51. Cendales LC, Kleiner DE, Hoffmann SC, Hale DA, Kampen R, Mannon RB, Swanson SJ, Kirk AD. Activity under the radar screen: analysis of subclinical rejection before and after treatment. Presented at the American Transplant Congress, Washington, D.C., 3 June 2003. 52. Pearl JP, McCoy KL, Wakefield T, Swanson SJ, Hale DA, Mannon RB, Cendales LC, Roederer M, Kirk AD. Repopulating cells after aggressive lymphocyte depletion are predominantly memory phenotype. Presented at the American Transplant Congress, Washington, D.C., 3 June 2003. 53. Mannon RB, Post D, Kowalski R, Hale DA, Swanson SJ, Kirk A, Britz J. Monitoring immune cell reconstitution using the Cylex® immune cell function assay (ImmunoKnow™). Presented at ASN 2003 Renal Week, 2003, San Diego, CA. 54. Pearl JP, Xu H, Christopher KL, Leopardi F, Preston E, Cendales L, Hale DA, Kirk AD. Aggressive lymphocyte depletion does not eliminate immune memory. Presented at the American Transplant Congress, Boston, Massachusetts, 16 May 2004. 55. Pearl JP, Parris J, McCoy KL, Hoffmann SC, Christopher KL, Xu H, Mannon RB, Hale DA, Swanson SJ, Kirk AD. Immunocompetent memory T-cells are the dominant cell type following antibody-mediated T-cell depletion and may be a barrier to achieving tolerance. Presented at the American Transplant Congress, Boston, Massachusetts, 16 May 2004. 56. Mannon RB, Hoffmann SC, Kampen R, Cheng OH, Hale DA, Kirk AD, Kleiner DE. Death and destruction: the molecular and cellular events of polyomavirus nephropathy. Presented at the American Transplant Congress, Boston, Massachusetts, 17 May 2004. 57. Hoffmann SC, Pearl JP, Hale DA, Mannon RB, Swanson SJ, Kirk AD. Ealy allograft rejection is mediated by CD3+CD4+CD45RA-CD62L- memory cells following alemtuzumab depletion. Presented at the American Transplant Congress, Boston, Massachusetts, 17 May 2004. 58. Akpinar E, Keary JM, Preston E, Xu H, Kurlander R, Hale DA. The trials and tribulations of translating a murine tolerance model to the nonhuman primate. Presented at the American Transplant Congress, Boston, Massachusetts, 18 May 2004. 59. Elster EA, Chamberlain C, Salaita C, Kirk AD, Hale DA, Mannon RB. Steroids have no calories: weight gain post transplantation is not prevented by steroid avoidance. Presented at the American Transplant Congress, Boston, Massachusetts, 18 May 2004. 60. Chamberlain CE, Ester E, Hale DA, Kirk AD, Daniels CE, Mannon RB. Weaker and weaker still: steroid avoidance does not prevent bone loss following kidney transplantation. Presented at the American Transplant Congress, Boston, Massachusetts, 18 May 2004.

Page 13

61. Elster E, Chamberlain C, Salaita C, Kirk A, Hale DA, Mannon R. Steroids have no calories: Weight gain post transplantation is not prevented by steroid avoidance. Presented at the XX International Congress of the Transplantation Society, Vienna, Austria, 10 September 2004. 62. Bruno D, Cheng O, Hale DA, Dhanireddy K, Kirk AD, Major EO, Major EO, Mannon RB. Limiting overimmunosuppression post transplant: the role of BK polyoma monitoring. Presented at the American Transplant Congress, Seattle, Washington, 22 May 2005. 63. Anam K, Kampen RL, Hale DA. T cell regulation does not contribute to the maintenance of tolerance in a mixed chimerism model. Presented at the American Transplant Congress, Seattle, Washington, 22 May 2005. 64. Dhanireddy KK, Xu H, Bruno DA, Ahang X, Leopardi FV, Johnson LB, Hale DA, Kirk AD. Pretransplant portal venous donor specific transfusion in conjunction with sirolimus prolongs renal allograft survival in non-human primates. Presented at the American Transplant Congress, Seattle, Washington, 23 May 2005. 65. Elster EA, Chamberlin C, Mannon RB, Swanson SJ, Kirk AD, Hale DA. Three year experiencewith alemtuzumab induction. Presented at the American Transplant Congress, Seattle, Washington, 25 May 2005. 66. Xu H, Hale DA, Kirk AD. Generation of a new rabbit anti-human leukocyte polyclonal antibody and its potential therapeutic application in preventing allo-immune responses. Presented at the World Transplant Congress, Boston, Massachussetts, 24 July 2006. 67. Bruno DA, Xu H, Hale DA, Kirk AD. A unique polyclonal antibody (xuALG) targets memory in the rhesus macaque. Presented at the World Transplant Congress, Boston, Massachussetts, 24 July 2006. 68. Kirk AD, Ford E, Fischer S, Hale DA, Cohen J, Mannon RB. Ebstein Barr virus as a biological indicator of immunosuppression in human renal transplantation. Presented at the World Transplant Congress, Boston, Massachussetts, 24 July 2006. 69. Crawford S, Bhusry A, Ford E, Hale DA, Mannon RB, Kirk AD. Sirolimus or tacrolimus: does either uniquely facilitate clinical donor specific hyporesponsiveness? Presented at the World Transplant Congress, Boston, Massachussetts, 24 July 2006. 70. Xu H, Preston E, Leopardi F, Hale DA, Kirk AD. CD25 Blockade does not break transplantation tolerance in nonhuman primates. Presented at the World Transplant Congress, Boston, Massachussetts, 25 July 2006. 71. Chamberlain C, Mannon RB, Penzak S, Alfaro R, Wesley R, Hale DA, Kirk AD. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Presented at the World Transplant Congress, Boston, Massachussetts, 25 July 2006.

Page 14

72. Crane N, Hale DA, Pinto P, Gage F, Tadaki D, Kirk AD, Levin I, Elster E. Non-invasive renal vessel differentiantion during laparoscopic donor nephrectomies. Presented at the World Transplant Congress, Boston, Massachussetts, 27 July 2006. 73. Ford E, Mannon RB, Cropper T. Hale L, Jordan S, Koussis P, Hale DA, Kirk AD. A comprehensive strategy for informed consent and trial enrollment in transplantation. Presented at the World Transplant Congress, Boston, Massachussetts, 27 July 2006. 74. Kleiner DF, Ferhane D, Cheng O, Hale DA, Kirk AD, Mannon RB. Serial immunohistochemical characterization of the onset of transplant glomerulopathy. Presented at the World Transplant Congress, Boston, Massachussetts, 27 July 2006.

Page 15

Posters 1. Lane B, Hale DA, Molloy M, Dubois A. Effects of Perioperative Administration of Motilin on Postoperative Gastric Ileus and Gastric Acid Secretion in a Canine Model. Presented at Society for Surgery of the Alimentary Tract, 15 May 1995, San Diego, California. 2. Hale DA, Gottschalk R, Wood ML, Maki T, Monaco AP. The monoclonal fusion protein CTLA-4Ig synergizes with rapamycin and cyclosporine in prolonging skin allograft survival. American Society of Transplant Surgeons, Dallas, Texas, 30 May 1996. 3. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Prolongation of skin allo and xenograft survival in mice treated with rapamycin, antilymphocyte serum and donor specific bone marrow transfusion. Presented at XVI International Congress of the Transplantation Society, Barcelona, Spain, 25 August 1996. 4. Hale DA, Gottschalk R, Wood ML, Maki T, Monaco AP. Prolongation of skin allograft survival in mice treated with CTLA-4Ig in combination with rapamycin, cyclosporine and/or antilymphocyte serum. Presented at XVI International Congress of the Transplantation Society, Barcelona, Spain, 25 August 1996. 5. Hale DA, Gottschalk R, Maki T, Monaco AP. Induction of donor specific tolerance and chimerism with a single dose of sirolimus in antilymphocyte serum (ALS) treated, donor specific bone marrow (BM) injected mice. Presented at the Fifth Basic Science Symposium of The Transplantation Society, Chautauqua, New York, 6 September 1997. 6. Hale DA, Gottschalk R, Maki T, Monaco AP. Temporal relation of immunoregulatory (suppressor) cell function and skin graft survival in mice treated with sirolimus, antilymphocyte serum and donor specific bone marrow. Presented at the 17th Annual Meeting, American Society of Transplant Physicians, Chicago, Illinois, 10-13 May 1998. 7. Hale DA, Gottschalk R, Maki T, Monaco AP. Suppressor mechanisms in mice treated with sirolimus, antilymphocyte serum and donor specific bone marrow. Presented at the 17th World Congress, The Transplantation Society, Montreal, Canada, 12-17 July 1998. 8. Hale DA, Gottschalk R, Maki T, Monaco AP. Sirolimus facilitates induction of chimerism in antilymphocyte serum and donor bone marrow treated mice. Presented at the 17th World Congress, The Transplantation Society, Montreal, Canada, 12-17 July 1998. 9. Hale DA, Gottschalk R, Maki T, Monaco AP. Mechanistic characterization of tolerance induced with ALS, donor bone marrow and sirolimus. Presented at the 18th Annual Meeting of the American Society for Transplantation, Chicago, Illinois, 15-19 May 1999. 10. Hale DA, Gottschalk R, Maki T, Monaco AP. Suppressor cell activity in mice rendered tolerant with ALS, donor bone marrow and sirolimus. Presented at Transplantation 2000, Chicago, Illinois, 12 May 2000. 11. Cendales LC, Kleiner D, Burns C, Hale DA, Kirk AK, Granger D, Breidenbach WC.

Page 16

Histopathology of rejection in composite tissue allotransplantation. Presented at the American Transplant Congress, Washington, D.C., 28 April 2002 12. Singh KA, Hale DA, Hoffmann SC, Kampen RL, Kleiner DE, Mannon RB, Swanson SJ, Tadaki DK, Kirk AD. Renal tubule epithelial cell derived MCSF as a potential instigator of post-ischemic monocyte recruitment. Presented at the American Transplant Congress, Washington, D.C., 28 April 2002 13. Anam K, Akpinar E, Smoot DS, Harlan DM, Hale DA. Abrogation of alloantibody response in a complete mismatch murine skin allograft model. Presented at the American Transplant Congress, Washington, D.C., 29 April 2002 14. Akpinar E, Smoot DS, Craighead N, Harlan DM, Hale DA. Short and long term kinetics of hematopoetic chimerism in mice rendered tolerant with ALS, sirolimus and donor bone marrow. Presented at the American Transplant Congress, Washington, D.C., 29 April 2002 15. Akpinar E, Craighead N, Anam K, Harlan DM, Hale DA. Enrichment for C-Kit positive cells greatly increases the tolerogenic efficacy of donor bone marrow infused with ALS and sirolimus. Presented at the American Transplant Congress, Washington, D.C., 29 April 2002 16. Hoffmann, SC, Kampen RL, Amur S, Sharaf MA, Kleiner DE, Swanson SJ, Hale DA, Mannon RB, Harlan DM, Blair PJ, Kirk AD. Evidence that reversible renal allograft rejection in patients with clinically normal renal allograft fuction precipitates chronic allograft nephropathy. Presented at the American Transplant Congress, Washington, D.C., 30 April 2002 17. Akpinar E, Park J, Chute JP, Harlan DM, Hale DA. Donor bone marrow retains its tolerogenic efficacy following in vitro expansion. Presented at the XIX International Congress of the Transplantation Society, Miami, Florida, 26 August 2002 18. Anam K, Akpinar E, Smoot DS, Harlan DM, Hale DA. Abrogation of alloantibody response in a complete mismatch murine skin allograft model. Presented at the XIX International Congress of the Transplantation Society, Miami, Florida, 26 August 2002 19. Singh KA, Hale DA, Hoffmann SC, Kampen RL, Kleiner DE, Mannon RB, Swanson SJ, Tadaki DK, Kirk AD. Renal tubule epithelial cell derived MCSF as a potential instigator of post-ischemic monocyte recruitment. Presented at the XIX International Congress of the Transplantation Society, Miami, Florida, 26 August 2002 20. Swanson SJ, Hale DA, Cendales L, Kirk AD, Mannon RB. Monitoring immunosuppression following kidney transplantation: experience with the Cylex Immune Cell Function Assay. Presented at the American Society of Nephrology Meeting, Philadelphia, PA, 2 November 2002 21. McCoy KL, Pearl JP, Sayyar S, Hoffman SC, Perfetto S, DeRosa S, Cendales LC, Hale DA, Swanson SJ, Mannon RB, Roederer M, Kirk AD. Elevation of natural killer cell populations associated with acute rejection following T cell depletion. Presented at the American Transplant Congress, Washington, D.C., 1 June 2003.

Page 17

22. Becker, BN, Hoffmann S, Amur S, Muehrer RJ, Jacobson LM, Hale DA, Kampen R, Kleiner D, Mannon R, Swanson SJ, DelRio A, Hullett D, Kirk AD. Is the stable graft fated for chronic allograft nephropathy? Presented at the American Transplant Congress, Washington, D.C., 1 June 2003. 23. Akpinar E, Keary JM, Preston E, Craghead M, Xu H, Kurlander R, Hale DA. Donor bone marrow infusion accelerates alloantibody sensitization in cynomolgus monkeys treated with anti-thymocyte globulin and sirolimus. Presented at the American Transplant Congress, Washington, D.C., 1 June 2003. 24. Akpinar E, Craighead N, Anam K, Park J, Hale DA. Successful induction of chimerism using ex-vivo expanded donor bone marrow and a nonmyeloablative conditioning regimen. Presented at the American Transplant Congress, Washington, D.C., 1 June 2003. 25. Chamberlain CE, Kirk AD, Hale DA, Swanson SJ, Cendales LC, Mannon RB. Prednisone decreases sensitivity to sirolimus in kidney transplant recipients. Presented at the American Transplant Congress, Washington, D.C., 2 June 2003. 26. Anam K, Black A, Hale DA. Low dose titratable macrochimerism in fully allogeneic mice treated with T cell depletion, sirolimus and donor bone marrow. Presented at the American Transplant Congress, Boston, Massachusetts, 16 May 2004. 27. Akpinar E, Craighead N, Anam K, Smoot D, Hale DA. C-kit+lin+ fraction of donor bone marrow possesses superior potency compared to whole BM in prolonging skin allograft survival in mice treated with ALS and sirolimus. Presented at the American Transplant Congress, Boston, Massachusetts, 16 May 2004. 28. Mannon RB, Post D, Kowalski R, Kirk AD, Hale DA, Britz J. Assessing immune reconstitution: monitoring lymphocyte immune function following depletional therapy using the ImmunknowTM assay. Presented at the American Transplant Congress, Boston, Massachusetts, 16 May 2004. 29. Akpinar E, Park J, Hale DA. Establishment of a bone marrow expansion system for ex vivo generation of cells with potent capacity to prolong skin graft survival. Presented at the American Transplant Congress, Boston, Massachusetts, 17 May 2004. 30. Hoffman SC, Kampen R, Pearl JP, Hale DA, Jacobson LM, Kleiner DE, Mannon RB, Muehrer RJ, Swanson SJ, Becker BN, Kirk AD. The new standard of care: alemtuzumab induction with tacrolimus and sirolimus maintenance immunosuppression to limit acute and chronic allograft rejection. Presented at the American Transplant Congress, Boston, Massachusetts, 17 May 2004. 31. Akpinar E, Keary JM, Kurlander R, Hale DA. Measurement of chimerism in cynomolgus monkeys using a human specific short tandem repeat base assay. Presented at the American Transplant Congress, Boston, Massachusetts, 17 May 2004. 32. Elster EA, Hale DA, Cendales LB, Kleiner D, Ring M, Niles B, Swanson SJ, Mannon RB,

Page 18

Kirk AD. Correlation of renal resistance index and biopsy proven chronic allograft nephropathy: a part of the general transplant physical exam. Presented at the American Transplant Congress, Boston, Massachusetts, 18 May 2004. 33. Elster E, Hale DA, Cendales L, Kleiner D, Ring M, Niles B, Swanson S, Mannon R, Kirk A. Correlation of renal resistance index and biopsy proven chronic allograft nephropathy: A part of the general transplant physical exam. Presented at the XX International Congress of the Transplantation Society, Vienna, Austria, 10 September 2004. 34. Hon YY, Chamberlain C, Hale DA, Kirk AD, Mannon RB. Tacrolimus abbreviatied area under the curve correlates with trough concentration and indicates graft histology. Presented at the World Transplant Congress, Boston, Massachussetts, 24 July 2006. 35. Hale DA, Hoffman SC, Kleiner DE, Mannon RB, Kampen RI, Jacobson LM, Swanson SJ, Becker BN, Kirk AD. Kidney allograft rejection is associated with upregulation of chemokine transpcripts that precede histologic changes. Presented at the World Transplant Congress, Boston, Massachussetts, 25 July 2006. 36. Crane N, Hale DA, Pinto P, Gage F, Tadaki D, Levin I, Kirk AD, Elster E. Pneumoperitoneum has no effect of tissue oxygenation during laparoscopic donor nephrectomy using visible light collected by the 3-ccd camera. Presented at the World Transplant Congress, Boston, Massachussetts, 26 July 2006. 37. Xu H, Kampen RL, Bhusry A, Hale DA, Kirk AD. Immune-modulation and induction of regulatory phenotype T cells by a new generation of rabbit anti-human leukocyte polyclonal antibody. Presented at the World Transplant Congress, Boston, Massachussetts, 26 July 2006. 38. Elster E, Gage F, Tadaki D, Hale DA, Leeser D, Fernandez C, Destephano D, Kirk AD, Gorbach A. Infrared imaging of cadaveric organ viability with pulsatile perfusion. Presented at the World Transplant Congress, Boston, Massachussetts, 27 July 2006. 39. Gage F, Gorbach A, Hale DA, Tadaki D, Lesser D, Fernandez C, Destephano D, Kirk AD, Wang H, Elster E. Assessment of pharmacologic resuscitation during pulsatile perfusion. Presented at the World Transplant Congress, Boston, Massachussetts, 27 July 2006. 40. Hale DA. Adoption of a web-based curriculum has no impact on resident ABSITE scores. Presented at the Southern Group on Educational Affairs Meeting, Nashville, Tennessee, 4 April 2008.

Page 19

Invited Lectures/Grand Rounds 1. Small bowel transplantation in non-human primates. Oregon Health Sciences University; Portland Oregon. 12 November 1990. 2. Tolerance induction strategies using ALS, rapamycin and donor bone marrow infusion. Wyeth Symposium; Boston, Massachusetts. 2 November 1999 3. Induction of tolerance and multilineage chimerism using ALS, rapamycin and donor bone marrow infusion. Current Trends in Immunosuppression; Geneva, Switzerland. 16 February 2000. 4. Historical development of bone marrow conditioning regimens for the induction of allograft tolerance. National Institutes of Health; Bethesda, Maryland. 24 February 2000. 5. Mechanistic characterization of tolerance induced by the administration of ALS, rapamycin and donor bone marrow. National Institutes of Health; Bethesda, Maryland. 25 February 2000. 6. Induction of tolerance and multilineage chimerism using ALS, rapamycin and donor bone marrow infusion. National Institutes of Health; Bethesda, Maryland. 5 July 2000. 7. An overview of the intramural transplant program at NIH. Beth Israel Deaconess Medical Center; Boston, Massachusetts. 29 May 2001. 8. Determinants of long term graft survival. Contemporary Forums in Transplantation; Crystal City, Virginia. 27 September 2001. 9. Bone marrow conditioning in solid organ transplantation. AI Dupont Children’s Hospital; Wilmington, Delaware. 11 February 2002. 10. Kidney transplantation without steroids or calcineurin inhibitors. UNOS Clinical Forum. Bethesda, Maryland 14 March 2002. 11. Sirolimus monotherapy in kidney transplantation. Mt Sinai Medical Center, New York, New York. 15 April 2002. 12. Depletional induction strategies followed by monotherapy maintenance immunosuppression in kidney transplantation. Downstate Medical Center, New York, New York. 16 April 2002. 13. Tolerance strategies in kidney transplantation. Beth Israel Deaconess Medical Center, Boston, Massachusetts. 22 April 2002. 14. Paul Peters Lecture, Tolerance induction, the current state of the art. Texas State Transplantation Society Annual Meeting. Austin, Texas. 21 June 2002. 15. Experimental approaches to tolerance induction, Fifth International Symposium on Renal Transplantation in Aguascalientes-México, 26 July 2002. 16. Clinical application of tolerance induction protocols, Fifth International Symposium on Renal

Page 20

Transplantation in Aguascalientes-México, 26 July 2002. 17. Current concepts in tolerance induction. NATCO Transplant Institute. San Diego, California, 15 March 2003. 18. Immunologic monitoring of the transplant recipient: challenges and approaches using antibody induction. New Horizons I Antibody Induction Therapy. Chicago, Illinois, 21 March 2003. 19. Preparation for a career in solid organ transplantation. Medical and Dental Preparatory Association, University of Texas at Arlington. Arlington, Texas, 2 April 2003. 20. Immunologic mechanisms involved in the induction and maintenance of allotransplantation tolerance. Department of Biology Seminar, University of Texas at Arlington. Arlington, Texas, 3 April 2003. 21. Tolerance induction. Frontiers in Science Lecture, University of Texas at Arlington. Arlington, Texas, 4 April 2003. 23. Introduction to immunologic tolerance. Distinguished Professors Lecture, Uniformed Services University of the Health Sciences. Bethesda, Maryland, 28 August 2003. 24. Current progress in clinical and experimental tolerance induction. Grand Rounds, University of Texas Health Sciences Center, San Antonio, Texas, 12 September 2003. 25. Strategies for reducing or eliminating the need for chronic immunosuppression in transplant recipients through the use of donor hematopoetic stem cells. ASHI Plenary Session, 30 October 2003. 26. Monitoring transplant patients receiving induction therapy with alemtuzumab. Presented at the American Transplant Congress, Boston, Massachusetts, 16 May 2004. 27. Tolerance strategies employing polyclonal anti-lymphocyte globulin. Presented at II Corso di Aggiornamento su Trapianto di Rene, Pavia, Italy, 24 September 2004. 28. Impact of immunosuppression on regulatory T cell function. Presented at ASTS Winter Meeting, Miami, Florida, 21 January 2005. 29. The current state of xenotransplantation. Presented at the Minority Organ Donor Investigators' meeting, Honolulu, Hawaii, 25 February 2005. 30. Immunologic consequences of alemtuzumab induction therapy in kidney transplant recipients. Toronto General Hospital, Toronto, Cananda, 11 May 2005.

Page 21

Publications 1. Hale DA, Cohen AJ, Schaefer P, Jordan D, Thompson LD, Bellamy RF, Edwards FH, Barry MJ: The use of computed tomography in the evaluation of patients with myasthenia gravis. Southern Medical Journal 1990; 83: 414-416. 2. Hale DA, Waldorf K, Kleinschmidt J, Pearl RH, Seyfer A. Small bowel transplantation in non-human primates. J Ped Surg 1991; 26: 914-920. 3. Edwards FH, Hale DA, Cohen A, Thompson L, Pezzella AT, Virmani R. Primary cardiac valve tumors. Ann Thorac Surg 1991; 52: 1127-31 4. Hale DA, Solla JA. Complete colonic obstruction caused by a sigmoid colon cancer incarcerated in an inguinal hernia sac. Southern Medical Journal 1991; 84: 1280-1281. 5. Hale DA, Cook JF, Baniqued A, Silva-Hale A, Molloy M, Pearl R, Hadro N, Jaques D. Selective digital enhancement of conventional film mammography. Journal of Surgical Oncology 1994; 55: 42-46. 6. Pearl RH, Hale DA, Molloy M, Schutt DC, Jaques DP. Pediatric Appendectomy. Journal of Pediatric Surgery 1995; 30: 173-181. 7. Goff JM, Molloy M, Debbas MT, Hale DA, Jaques DP. Long term impact of previous breast biopsy on breast cancer screening modalities. Journal of Surgical Oncology 1995; 59: 18-20. 8. Molloy M, Batzri S, Dziki AJ, Goldberg WJ, Hale DA, Harmon JW. Reversibility of deoxycholate induced cellular hypercalcemia in rabbit gastric mucosal cells. Surgery 1996; 119(1): 89 - 97. 9. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Prolongation of skin allograft survival in mice treated with rapamycin, antilymphocyte serum and donor specific bone marrow transfusion. Transplantation Proceedings 1996; 28: 3269. 10. Hale DA, Gottschalk R, Wood ML, Maki T, Monaco AP. Prolongation of skin allo and xenograft survival in mice treated with CTLA4-Ig in combination with rapamycin or cyclosporine. Transplantation Proceedings 1996; 28: 3270-3271. 11. Hale DA, Jaques DP, Molloy M, Pearl RH, Schutt DC, d’Avis J. Appendectomy: improving care through quality improvement. Archives of Surgery 1997; 132: 153-157. 12. Hale DA, Molloy M, Pearl RH, Schutt DC, Jaques DP. Appendectomy: a contemporary appraisal. Annals of Surgery 1997; 225: 252-261. 13. Hale DA, Gottschalk R, Fukuzaki T, Wood ML, Maki T, Monaco AP. Superiority of rapamycin over cyclosporine in augmenting skin allo and xenograft survival in mice treated with antilymphocyte serum and donor specific bone marrow. Transplantation 1997; 63: 359-364.

Page 22

14. Hale DA, Gottschalk R, Maki T, Monaco AP. The use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation 1997; 64: 897-900. 15. Hale DA, Gottschalk R, Maki T, Monaco AP. Determination of an improved sirolimus (rapamycin) based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor specific bone marrow. Transplantation 1998, 65: 473-479. 16. Hale DA, Gottschalk R, Maki T, Monaco AP. The use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow (DSBM) in antilymphocyte serum treated mice: the unique effect of sirolimus. Transplantation Proceedings 1998, 30(5): 2432-2434. 17. Hale DA, Umore A, Gottschalk R, Maki T, Monaco AP. Establishment of Stable Multilineage Hematopoietic Chimerism and Donor-Specific Tolerance Without Irradiation. Transplantation 2000, 69(7): 1242-1251. 18. Montgomery SP, Hale DA, Hirshberg B, Harlan DM, Kirk AD. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunologic Reviews 2001, 183: 214-222. 19. Monaco AP, Maki T, Hale DA, Umemura A, Morita H The enigma of tolerance and chimerism: variable role of T cells and chimerism in induction of tolerance with bone marrow. Transplant Proceedings 2001, 33(7-8): 3837-3839. 20. Montgomery SP, Mog SR, He X, Tadaki DK, Hale DA, Hirshberg B, Berning JD, Leconte J, Harlan DM, Kirk AD. Efficacy and toxicity of a steroid sparing renal allograft protocol using sirolimus, tacrolimus and daclixumab in a non-human primate renal allograft model. American Journal of Transplantation 2002, 2: 381-385 21. Hirshberg B, Montgomery S, Wysoki MG, Tadaki D, Lee J, Hines K, Gaglia J, Patterson N, Leconte J, Hale D, Chang R, Kirk AD, Harlan DM. Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes 2002, 51: 2135 - 2140 22. Hale DA, Gottschalk R, Umore A, Maki T, Monaco AP. Immunological mechanisms in tolerance produced in mice with non-radiation based lymphoablation and donor specific bone marrow. Transplantation 2002, 74: 477 - 484. 23. Swanson SJ, Hale DA, Mannon RB, Kleiner DE, Chamberlain CE, Polly SM, Harlan DM, Kirk AD. Sirolimus monotherapy for the prevention of human renal allograft rejection following induction therapy with polyclonal rabbit anti-thymocyte globulin. Lancet 2002, 360: 1662 - 1664. 24. Hoffmann SC, Kampen RL, Amur S, Sharaf MA, Kleiner DE, Hunter K, Swanson SJ, Hale DA, Mannon RB, Blair PJ, Kirk AD. Molecular and immunohistochemical characterization of

Page 23

the onset and resolution of human renal allograft ischemia/reperfusion injury. Transplantation 2002, 74: 916 - 923. 25. Xu H, Montgomery SP, Preston EH, Tadaki DK, Hale DA, Harlan DM, Kirk AD. Studies investigating pretransplant donor-specific blood transfusion, rapamycin and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. Journal of Immunology 2003, 170: 2776 – 2782. 26. Cendales LC, Swanson SJ, Kirk AD, Mannon RB, Hale DA. Delayed autotransplantation of a solitary kidney facilitated by pump perfusion preservation. Surgery 2003, 133: 438 - 439. 27. Hirshberg B, Preston EH, Xu H, Wysoki MG, Neeman Z, Bunnell D, Soleimanpour S, Hale DA, Kirk AD, Harlan DM. Rabbit anti-thymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a non-human primate islet transplantation model. Transplantation 2003, 76: 55-60. 28. Kirk AD, Hale DA, Mannon RB, Kleiner D, Hoffmann SC, Kampen RL, Cendales LK, Tadaki

DK, Harlan DM, Swanson SJ. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody campath-1H. Transplantation 2003, 76: 120-129. 29. Gorbach A, Simonton D, Hale DA, Swanson SJ, Kirk SD. Objective, Real-time, intraoperative assessment of renal perfusion using infrared imaging. American Journal of Transplantation 2003, 3: 988-993. 30. McNally M, Mannon RB, Javor ED, Swanson SJ, Hale DA, Gorden P, Kirk AD. Successful renal transplantation in a patient with congenital generalized lipodystrophy. A case report. American Journal of Transplantation 2004, 4: 447-449. 31. Akpinar E, Craighead N, Smoot D, Hale DA. Potent skin allograft survival prolongation using a committed progenitor fraction of bone marrow in mice. Transplantation 2004, 78(3): 383-391. 32. Anam K, Akpinar E, Craighead N, Black AT, Hale DA. Targeted T cell inhibition supplants polyclonal antilymphocyte serum and produces tolerance and mixed chimerism in mice conditioned with sirolimus and donor bone marrow. Transplantation 2004, 78(9): 1290-1298. 33. Hoffmann SC, Hale DA, Kleiner DE, Mannon RB, Kampen R, Jacobson LM, Cendales LC, Swanson SJ, Becker BN, Kirk AD. Functionally significant renal allograft rejection is defined by transcriptional criteria. American Journal of Transplantation 2005, 5: 573-581. 34. Akpinar E, Keary JM, Kurlander R, Hale DA. Measurement of chimerism in cynomolgus monkeys using human specific short tandem repeat based assay. Transplantation 2005, 79(2): 236-239. 35. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, Swanson SJ, Mannon RB, Roederer M, Kirk AD. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. American Journal of Transplantation 2005, 5: 465-474.

Page 24

36 Elster EA, Hale DA, Mannon RB, Cendales LC, Kleiner DE, Swanson SJ, Kirk AD. The surgical transplant physical exam: correlation of renal resistance index and biopsy proven chronic allograft nephropathy. Journal of the American College of Surgeons 2005, 200(4): 552-556. 37. Preston EH, Xu H, Dhanireddy KK, Pearl JP, Leopardi FV, Starost MF, Hale DA, Kirk AD. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant. 2005, 5(5):1032-1041. 38. Chamberlain CE, Fitzgibbon E, Wassermann EM, Butman JA, Kettl D, Hale DA, Kirk AD, Mannon RB. Idiopathic intracranial hypertension following kidney transplantation: A case report and review of the literature. Pediatric Transplantation 2005, 9: 545-550. 39. Kirk AD, Mannon RB, Kleiner DE, Swanson SJ, Kampen RL, Cendales LK, Elster EA, Wakefield T, Chamberlain C, Hoffmann SC, Hale DA. Results from a human renal allograft tolerance trial evaluating t-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005, 80: 1051-1059. 40. Mannon RB,Hoffmann SC, Ryschkewitsch C,Curfman B, Kampen RL, Cheng OC, Kleiner DE, Ryschkewitsch C, Curfamn B, Major E, Hale DA, Kirk AD. Molecular Evaluation of BK Polyomavirus Nephropathy. American Journal of Transplantation 2005, 5: 2883-2893. 41. Kirk AD, Hale DA, Ford E, Kleiner DE, Kapmpen RL, Elster EA, Swanson SJ, Cendales LC, Cropper T, Hale L, Jordan S, Koussis T, Peretti J, Sloane A, Salaita C, Ring M, Chamberlain C, Mannon RB. Solid organ transplantation at the National Institutes of Health: development of a research-based transplantation practice. Clin Transpl 2005, : 131-144. 42. Anam K, Black AT, Hale DA. Low dose busulfan facilitates chimerism and tolerance in a murine model. Transplantation Immunology 2006, 15: 199-204. 43. Bolanowski A, Mannon RB, Holland SM, Malech HL, Aschan J, Palmblad J, Hale DA, Kirk AD. Successful renal transplantation in patients with chronic granulomatous disease. Am J Transplant 2006, 6:636-9. 44. Pomfret EA, Feng S, Hale DA, Magee JC, Mulligan M, Knechtle SJ. The Art and Science of Immunosuppression: the Fifth Annual American Society of Transplant Surgeon's State-of-the-Art Winter Symposium. Am J Transplant 2006, 6:275-80. 45. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006, 6: 1084-1085. 46. Chamberlain CE, Penzak S, Alfaro RM, Wesley R, Daniels CE, Hale DA, Kirk AD, Mannon RB. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008, 8(6): 1297-1302.

Page 25

47. Crane NJ, Pinto PA, Hale DA, Gage FA, Tadaki D, Kirk AD, Levin IW, Elster EA. Non-invasive monitoring of tissue oxygenation during laparoscopic donor nephrectomy. BMC Surg 2008, 8: 8. 48. Elster EA, Leeser DB, Morrissette C, Pepek JM, Quiko A, Hale DA, Chamberlain C, Salaita C, Kirk AD, Mannon RB. Obesity following kidney transplantation and steroid avoidance immunosuppression. Clin Transplant 2008, 22(3): 354-359. 49. Hon YY, Chamberlain CE, Kleiner DE, Ring MS, Hale DA, Kirk AD, Mannon RB. Low tacrolimus trough and abbreviated area-under-the-curve correlate with biopsy-proven acute rejection in kidney transplantation. Submitted to Am J Transplant 2008, 8: 1297-1302. 50. Dhanireddy KK, Bruno DA, Weaver TA, Xu H, Zhang X, Leopardi FV, Hale DA, Kirk AD. Portal Venous Donor Specific Transfusion in Conjunction with Sirolimus Prolongs Renal Allograft Survival in Non-Human Primates. Am J Transplant 2009, 9: 124-131. 51. Gorbach AM, Leeser DB, Wang H, Tadaki DK, Fernandez C, DeStephano D, Hale DA, Kirk AD, Gage FA, Elster EA. Assessment of Cadaveric Organ Viability during Pulsatile Perfusion Using Infrared Imaging. Transplantation, (in press).

Page 26

Book Chapters and Invited Reviews 1. Hale DA, Dubois A. Complications of peptic ulcer disease. In Consultations in Gastroenterology. W. Snape ed., W.B. Saunders Company, 1996. 2. Hale DA, Monaco AP. Bone Marrow Conditioning in Transplantation. In Transplantation. LC Ginns, AB Cosimi, PJ Morris eds., Blackwell Science, Inc. 1999. 3. Hale DA, Swanson SJ, Mannon RB, Kleiner DE, Hoffman SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Kirk AD. Immunologic monitoring of the transplant recipient: challenges and approaches using antibody induction. Transplantation Reviews 2003, 17: S20-S25. 4. Dhanireddy KK, Xu H, Mannon RB, Hale DA, Kirk AD. The clinical application of monoclonal antibody therapies in renal transplantation. Expert Opinion in Emerging Drugs 2004, 9: 23-37. 5. Elster EA, Hale DA, Mannon RB, Cendales LB, Swanson SJ, Kirk AD. The road to tolerance. Transplant Immunology 2004, 13(2): 87-99. 6. Hale DA. Biological effects of induction immunosuppression. Current Opinion in Immunology 2004, 16(5): 565-570. 7. Hale DA, Kirk AD. MTOR inhibitors in Transplantation-Novel immunosuppressive strategies with sirolimus. Current Opinion in Organ Transplantation 2004, 9: 400-405. 8. Kirk AD, Swanson SJ, Mannon RB, Hale DA. Strategies for minimizing immunosuppression in organ transplantation, Transplant International 2005, 18: 2-14. 9. Hale DA, Dhanireddy K, Bruno D, Kirk AD. Induction of transplantation tolerance in nonhuman primate preclinical models. Philos Trans R Soc Lond B Biol Sci. 2005, 360(1461):1723-37. 10. Hale DA. Basic Transplantation Immunology. Surgical Clinics of North America 2006, 86: 1103-1125.